Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Other financing activities (2019 - 2023)

Eton Pharmaceuticals (ETON) has disclosed Other financing activities for 4 consecutive years, with -$1000.0 as the latest value for Q4 2023.

  • Quarterly Other financing activities changed N/A to -$1000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $180000.0 through Dec 2023, changed N/A year-over-year, with the annual reading at $180000.0 for FY2024, 0.0% changed from the prior year.
  • Other financing activities hit -$1000.0 in Q4 2023 for Eton Pharmaceuticals, down from $181000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.0 million in Q3 2021 to a low of -$1000.0 in Q4 2023.
  • Historically, Other financing activities has averaged $573214.3 across 4 years, with a median of $605000.0 in 2019.
  • Biggest five-year swings in Other financing activities: rose 5.8% in 2020 and later surged 84.38% in 2021.
  • Year by year, Other financing activities stood at $501000.0 in 2019, then soared by 54.29% to $773000.0 in 2020, then rose by 11.64% to $863000.0 in 2021, then tumbled by 100.12% to -$1000.0 in 2023.
  • Business Quant data shows Other financing activities for ETON at -$1000.0 in Q4 2023, $181000.0 in Q1 2023, and $863000.0 in Q4 2021.